Midcap biotech companies spent $746.8 million on research and development in the third quarter of 2012, an increase from $621.1 million in the same period of 2011, according to a report from GlobalData. The focus of research programs is cancer treatment, "which is driving peer group R&D expenses higher," an analyst said.

Related Summaries